Patricia McGoldrick, NP
Nurse Practitioner · New York, NYNPI 1023009230
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Neurelis, Inc. at 26.7% of the total. 2025 is the largest year on record at $55,597, 2.9 times the $18,871 reported in 2021. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 988 payments — averaging $204.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$54K
- Jazz Pharmaceuticals Inc.$49K
- UCB, Inc.$36K
- SK Life Science, Inc.$18K
- Otter Pharmaceuticals, LLC$12K
- Immedica Pharma US, Inc.$9K
- plus $23K from 40 others
What the payments were for
- Consulting fees$43,74522%
- Speaking & faculty fees$117,68658%
- Travel & lodging$16,8798%
- Food & beverage$23,82012%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$49,616
- Epidiolex$47,683
- Fintepla$33,179
- SYMPAZAN$17,137
- XCOPRI$15,872
- ZTALMY$8,253
- Neuroblate$3,227
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$1,950
- Fycompa$1,735
- NONE$1,250
- OXTELLAR XR$950
- QELBREE$125
How this compares
$202,151 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 34 | $189,594 |
| BriviactBrivaracetam | 64 | $87,583 |
| NayzilamMidazolam | 50 | $67,071 |
| FycompaPerampanel | 29 | $47,287 |
| AptiomEslicarbazepine Acetate | 30 | $46,284 |
| ValtocoDiazepam | 26 | $37,291 |
| Lacosamide | 144 | $30,029 |
| XcopriCenobamate | 22 | $27,672 |
| VimpatLacosamide | 13 | $22,385 |
| Clobazam | 148 | $15,141 |
| Carbamazepine ErCarbamazepine | 90 | $14,426 |
| TopamaxTopiramate | 13 | $13,512 |
| Divalproex Sodium | 198 | $12,231 |
| Levetiracetam | 242 | $11,585 |
| Oxtellar XrOxcarbazepine | 16 | $11,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam, Vimpat | $36,434 | $177,039127 claims |
| Eisai Inc.Fycompa | $3,276 | $47,28729 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $312 | $46,28430 claims |
| Neurelis, Inc.Valtoco | $53,928 | $37,29126 claims |
| SK Life Science, Inc.Xcopri | $17,951 | $27,67222 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $2,135 | $11,53916 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $73 | $3,77211 claims |
| Upsher-smith Laboratories LLCTopiramate | $149 | $1,904135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in New York
- Jodi LogerfoNew York$48K
- Aileen FerrickNew York$26K
- Tsz Isabel WongNew York$25K
- Chris BustamanteNew York$22K
- Mayra PozoNew York$14K
- Janet JohnsonNew York$12K
- Rachel RankinNew York$10K
- Richelle CassellNew York$10K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.